The tariff classification of Amprenavir (CAS-161814-49-9), imported in bulk form, and AGENERASE™ (amprenavir) Capsules and AGENERASE™ (amprenavir) Oral Solution, from the United Kingdom, France, Italy, Canada, Singapore, etc.
Reasoning
The tariff classification of Amprenavir (CAS-161814-49-9), imported in bulk form, and AGENERASE™ (amprenavir) Capsules and AGENERASE™ (amprenavir) Oral Solution, from the United Kingdom, France, Italy, Canada, Singapore, etc.
Cite this ruling
CBP Ruling F84948 (3004909010): The tariff classification of Amprenavir (CAS-161814-49-9), imported in bulk form, and AGENERASE™ (amprenavir) Capsules and AGENERASE™ (amprenavir) Oral Solution, from the United Kingdom, France, Italy, Canada, Singapore, etc.
Paste this into a product's override reason when citing this ruling as justification for a classification.
Other rulings for HS6 300490
The tariff classification of RIBASPHERE™ (ribavirin) capsules
The tariff classification of cough suppressant lozenges from England.
The tariff classification of dietary supplements from Italy
The tariff classification of IQUIX® (levofloxacin ophthalmic solution) 1.5%, imported in bulk and measured-dose forms, from Finland
The tariff classification of Pulmozyme® (dornase alfa) Inhalation Solution; Raptiva® (Efalizumab) for injection, subcutaneous; Rituxan® (Rituximab); TNKase™ (Tenecteplase); and Xolair® (Omalizumab) for subcutaneous use